Lineage Cell Therapeutics, Inc. (LCTX) Financial Analysis & Valuation | Quarter Chart
Lineage Cell Therapeutics, Inc. (LCTX)
LCTXPrice: $1.78
Fair Value: 🔒
🔒score
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa cli... more
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapi... more
Description
Shares
| Market Cap | $409.98M | Exchange | AMEX |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Brian Culley |
| IPO Date | 1992-03-05 | CAGR | 0.15% |
| Employees | 70 | Website | www.lineagecell.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
LCTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $357.00M | P/E Ratio | -6.14 |
| Forward P/E | -19.1 | PEG Ratio | — |
| P/S Ratio | 3.08 | P/B Ratio | 1.6 |
| P/CF Ratio | -1.65 | P/FCF Ratio | -1.62 |
| EPS | $-0.29 | EPS Growth 1Y | 167.57% |
| EPS Growth 3Y | -6.06% | EPS Growth 5Y | 62.58% |
| Revenue Growth 1Y | 24.05% | Gross Margin | 0.64% |
| Operating Margin | -3.25% | Profit Margin | -6.26% |
| ROE | -1.19% | ROA | -0.75% |
| ROCE | -0.44% | Current Ratio | 4.5 |
| Quick Ratio | 4.5 | Cash Ratio | 4.31 |
| Debt/Equity | 0.13 | Interest Coverage | — |
| Altman Z Score | -4.04 | Piotroski Score | 3 |